StockNow
Calendar
Log in
U.S. Markets

Eli Lilly (LLY) says orforglipron showed greater weight loss and A1C reduction than oral semaglutide 25mg at 52 weeks in a Phase 3 trial

StockNow breaking-news AI analysis

Eli Lilly announced that orforglipron demonstrated superior weight loss and A1C reduction compared with oral semaglutide 25mg at 52 weeks in a Phase 3 study.

2 stocks
LLYEli Lilly & Co.$1,188.10Current priceNVONovo-Nordisk A/S$38.31Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
FX/Bonds

[MARKET UPDATE] Strength in DXY weighing on EUR and GBP; a move which comes amidst a pick-up in global fixed benchmarks